Please login to the form below

Not currently logged in
Email:
Password:

FDA issues haloperidol cardiovascular prescribing update

The FDA has updated the warnings section of the prescribing information for J&J's Haldol treatment for psychosis

The FDA has updated the warnings section of the prescribing information for Johnson & Johnson's (J&J) Haldol (haloperidol) treatment for psychosis.

The label has been revised to include a new cardiovascular subsection regarding cases of sudden death, QT prolongation and Torsades de Pointes (TdP) in patients treated with haloperidol, especially when given intravenously, or at doses higher than recommended. Both cases refer to different types of ventricular tachycardia, where heart beat speed increases.

Although injectable haloperidol is only approved by the FDA for intramuscular injection, there is strong evidence that the intravenous administration of haloperidol is a relatively common off-label clinical practice.

There have been at least 28 case reports of QT prolongation and TdP, some with fatal outcome in the context of off-label intravenous haloperidol. Healthcare professionals should consider this new risk information when making individual treatment decisions for their patients.

According to Reuters, J&J's stock fell USD 0.26 to rest at USD 62.94 in 17 September afternoon trading on the New York Stock Exchange composite.

Atypical antipsychotics have replaced Haldol and posted sales of USD 11.5bn in 2006, according to IMS Health data. J&J does not routinely release Haldol sales figures.

18th September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...

Infographics